Sonolucent cranial windows for bedside ultrasound identification of MRI-concordant glioblastoma recurrence during outpatient surveillance: an imaging correlation pilot study.
6 affiliations
- 1Northwell, New Hyde Park, NY, USA.
- 2Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA.
- 3Northwell, New Hyde Park, NY, USA. [email protected].
- 4Department of Neurosurgery, Lenox Hill Hospital, New York, NY, USA. [email protected].
- 5New York Medical College School of Medicine, 40 Sunshine Cottage Rd, Valhalla, NY, 10595, USA. [email protected].
- 6Division of Neurology, Department of Neurosurgery, University of São Paulo, São Paulo, SP, Brazil.
Abstract
Background and objective
Glioblastoma (GBM) is characterized by near-universal recurrence after surgical resection, necessitating close postoperative surveillance. Although MRI remains the gold standard for detecting tumor progression, fixed imaging intervals may delay recognition of recurrence. Sonolucent cranial implants enable transcranioplasty ultrasound (TCUS), offering a potential point-of-care adjunct for interval monitoring between scheduled MRI studies. We evaluated the feasibility of identifying sonographic findings concordant with MRI-confirmed GBM recurrence during routine outpatient follow-up.Methods
We conducted a retrospective review of prospectively registered consecutive GBM patients who underwent tumor resection with placement of a sonolucent cranial implant (ClearFit®, Longeviti Inc., Baltimore, MD) at a single tertiary center (February 2023-November 2025). Patients were included if they developed MRI-confirmed recurrence and underwent TCUS within 6 weeks before or after the recurrence-detecting MRI. TCUS examinations were performed during routine outpatient visits and interpreted by a clinician blinded to MRI findings. MRIs were independently reviewed by board-certified neuroradiologists. TCUS findings were qualitatively compared with MRI-defined recurrence.Results
Of 13 patients with sonolucent implants, 8 developed MRI-confirmed recurrence within 13 months of resection, with a range of 1 to 13 months. Four underwent TCUS within six weeks of the recurrence-detecting MRI. In all four cases, TCUS demonstrated hyperechoic abnormalities spatially concordant with MRI-defined recurrence. Examinations were safely performed (n = 4) in the outpatient setting.Conclusion
TCUS through sonolucent cranial implants may demonstrate concordant findings with MRI-confirmed GBM recurrence. This preliminary series supports its spatial correlation to inform future studies that evaluate TCUS as a point-of-care adjunct for interval surveillance. Prospective studies are warranted to define standardized protocols and diagnostic performance.
Related
- Identification of Survival-Associated miRNA Signatures in Glioblastoma Using Next-Generation Sequencing
- Ultrasound-guided Aspiration and Sclerotherapy for Chronic Morel-Lavallée Lesions: A Two-Case Report with Magnetic Resonance Imaging Correlation
- Hydrocele of the Canal of Nuck Mimicking Inguinal Hernia in an Adult Woman: Ultrasound and Magnetic Resonance Imaging (MRI) Correlation.
- MedLP-HAFB-CLIP: Hierarchical Adaptive Large Model With Learnable Medical Prompts for Level II Ultrasound Standard Plane Identification
- Label-Scarce Ultrasound Biopsy Needle Identification Using Dynamics-Guided Prior Modeling
BibTeX
@article{thomas2026sonolucent,
title = {{Sonolucent cranial windows for bedside ultrasound identification of MRI-concordant glioblastoma recurrence during outpatient surveillance: an imaging correlation pilot study.}},
author = {Griffin Thomas and Shoaib A Syed and Samuel Latzman and Marcio Yuri Ferreira and Seth Mejia and Artur Shlifer and Vadim Zhigin and Tamika Wong and Sanskruti Sana Bokil and Sara Massimo and Raphael Bertani and John A Boockvar and Netanel Ben-Shalom and Randy S D'Amico},
journal = {Acta neurochirurgica},
year = {2026},
month = aug,
doi = {10.1007/s00701-026-06999-w},
url = {https://europepmc.org/article/MED/42902051},
note = {CC BY},
}
RIS
TY - JOUR
TI - Sonolucent cranial windows for bedside ultrasound identification of MRI-concordant glioblastoma recurrence during outpatient surveillance: an imaging correlation pilot study.
AU - Griffin Thomas
AU - Shoaib A Syed
AU - Samuel Latzman
AU - Marcio Yuri Ferreira
AU - Seth Mejia
AU - Artur Shlifer
AU - Vadim Zhigin
AU - Tamika Wong
AU - Sanskruti Sana Bokil
AU - Sara Massimo
AU - Raphael Bertani
AU - John A Boockvar
AU - Netanel Ben-Shalom
AU - Randy S D'Amico
PY - 2026
DA - 2026/08/01
JO - Acta neurochirurgica
DO - 10.1007/s00701-026-06999-w
UR - https://europepmc.org/article/MED/42902051
AB - Background and objective Glioblastoma (GBM) is characterized by near-universal recurrence after surgical resection, necessitating close postoperative surveillance. Although MRI remains the gold standard for detecting tumor progression, fixed imaging intervals may delay recognition of recurrence. Sonolucent cranial implants enable transcranioplasty ultrasound (TCUS), offering a potential point-of-care adjunct for interval monitoring between scheduled MRI studies. We evaluated the feasibility of identifying sonographic findings concordant with MRI-confirmed GBM recurrence during routine outpatient follow-up.Methods We conducted a retrospective review of prospectively registered consecutive GBM patients who underwent tumor resection with placement of a sonolucent cranial implant (ClearFit®, Longeviti Inc., Baltimore, MD) at a single tertiary center (February 2023-November 2025). Patients were included if they developed MRI-confirmed recurrence and underwent TCUS within 6 weeks before or after the recurrence-detecting MRI. TCUS examinations were performed during routine outpatient visits and interpreted by a clinician blinded to MRI findings. MRIs were independently reviewed by board-certified neuroradiologists. TCUS findings were qualitatively compared with MRI-defined recurrence.Results Of 13 patients with sonolucent implants, 8 developed MRI-confirmed recurrence within 13 months of resection, with a range of 1 to 13 months. Four underwent TCUS within six weeks of the recurrence-detecting MRI. In all four cases, TCUS demonstrated hyperechoic abnormalities spatially concordant with MRI-defined recurrence. Examinations were safely performed (n = 4) in the outpatient setting.Conclusion TCUS through sonolucent cranial implants may demonstrate concordant findings with MRI-confirmed GBM recurrence. This preliminary series supports its spatial correlation to inform future studies that evaluate TCUS as a point-of-care adjunct for interval surveillance. Prospective studies are warranted to define standardized protocols and diagnostic performance.
SN - 0001-6268
SN - 0942-0940
ER -